Patent application number | Description | Published |
20090304713 | BINDING AGENTS - Compositions and methods relating to epitopes of sclerostin protein, and sclerostin binding agents, such as antibodies capable of binding to sclerostin, are provided. | 12-10-2009 |
20100036091 | ANTIBODY-BASED DIAGNOSTICS AND THERAPEUTICS - Compositions and methods relating to sclerostin binding agents, such as antibodies and polypeptides capable of binding to sclerostin, are provided. | 02-11-2010 |
20110097342 | BINDING AGENTS - Compositions and methods relating to epitopes of sclerostin protein, and sclerostin binding agents, such as antibodies capable of binding to sclerostin, are provided. | 04-28-2011 |
20130203968 | ANTIBODY-BASED DIAGNOSTICS AND THERAPEUTICS - Compositions and methods relating to sclerostin binding agents, such as antibodies and polypeptides capable of binding to sclerostin, are provided. | 08-08-2013 |
Patent application number | Description | Published |
20140044761 | HYBRID FRAGRANCE ENCAPSULATE FORMULATION AND METHOD FOR USING THE SAME - A hybrid encapsulate formulation obtained by mixing a starch/fragrance emulsion with a core-shell capsule suspension is provided as is a method of using the formulation in a personal care product, a beauty care product, a fabric care product, a home care product, a personal hygiene product, an oral care product and a method for releasing an encapsulated fragrance by moisture, shear, or a combination thereof. | 02-13-2014 |
20140287008 | HYBRID POLYUREA FRAGRANCE ENCAPSULATE FORMULATION AND METHOD FOR USING THE SAME - A hybrid polyurea encapsulate formulation obtained by mixing a starch/fragrance emulsion with a polyurea capsule suspension is provided as is a method of using the formulation in a personal care product, a beauty care product, a fabric care product, a home care product, a personal hygiene product, an oral care product and a method for releasing an encapsulated fragrance by moisture, shear, or a combination thereof. | 09-25-2014 |
Patent application number | Description | Published |
20100168212 | OLIGOMERS - Molecules are provided for inducing or facilitating exon skipping in forming spliced mRNA products from pre-mRNA molecules in cells. The molecules may be provided directly as oligonucleotides or expression products of vectors that are administered to a subject. High rates of skipping can be achieved. High rates of skipping reduce the severity of a disease like Duchene Muscular Dystrophy so that the disease is more like Becker Muscular Dystrophy. This is a severe reduction in symptom severity and mortality. | 07-01-2010 |
20120065244 | OLIGOMERS - Molecules are provided for inducing or facilitating exon skipping in forming spliced mRNA products from pre-mRNA molecules in cells. The molecules may be provided directly as oligonucleotides or expression products of vectors that are administered to a subject. High rates of skipping can be achieved. High rates of skipping reduce the severity of a disease like Duchene Muscular Dystrophy so that the disease is more like Becker Muscular Dystrophy. This is a severe reduction in symptom severity and mortality. | 03-15-2012 |
20120108652 | OLIGOMERS - Molecules are provided for inducing or facilitating exon skipping in forming spliced mRNA products from pre-mRNA molecules in cells. The molecules may be provided directly as oligonucleotides or expression products of vectors that are administered to a subject. High rates of skipping can be achieved. High rates of skipping reduce the severity of a disease like Duchene Muscular Dystrophy so that the disease is more like Becker Muscular Dystrophy. This is a severe reduction in symptom severity and mortality. | 05-03-2012 |
20120108653 | OLIGOMERS - Molecules are provided for inducing or facilitating exon skipping in forming spliced mRNA products from pre-mRNA molecules in cells. The molecules may be provided directly as oligonucleotides or expression products of vectors that are administered to a subject. High rates of skipping can be achieved. High rates of skipping reduce the severity of a disease like Duchene Muscular Dystrophy so that the disease is more like Becker Muscular Dystrophy. This is a severe reduction in symptom severity and mortality. | 05-03-2012 |
20130289096 | Oligomers - Molecules are provided for inducing or facilitating exon skipping in forming spliced mRNA products from pre-mRNA molecules in cells. The molecules may be provided directly as oligonucleotides or expression products of vectors that are administered to a subject. High rates of skipping can be achieved. High rates of skipping reduce the severity of a disease like Duchene Muscular Dystrophy so that the disease is more like Becker Muscular Dystrophy. This is a severe reduction in symptom severity and mortality. | 10-31-2013 |
20140057964 | Oligomers - Molecules are provided for inducing or facilitating exon skipping in forming spliced mRNA products from pre-mRNA molecules in cells. The molecules may be provided directly as oligonucleotides or expression products of vectors that are administered to a subject. High rates of skipping can be achieved. High rates of skipping reduce the severity of a disease like Duchene Muscular Dystrophy so that the disease is more like Becker Muscular Dystrophy. This is a severe reduction in symptom severity and mortality. | 02-27-2014 |
Patent application number | Description | Published |
20120077551 | HIGH-VOLTAGE TOLERANT VOLTAGE REGULATOR - Circuits and methodologies related to high-voltage tolerant regulators are disclosed. In some implementations, a voltage regulator can be configured to be capable of being in a regulating state and a bypass state. In the regulating state, an input voltage greater than a selected value can be regulated so as to yield a desired output voltage such as a substantially constant voltage. In the bypass state, an input voltage at or less than the selected value can be regulated so as to yield an output voltage that substantially tracks the input voltage. Such a capability of switching between two modes can provide advantageous features such as reducing the likelihood of damage in a powered circuit due to high input voltage, and extending the operating duration of a power source such as a rechargeable battery. Also disclosed are examples of how the foregoing features can be implemented in different products and methods of operation and fabrication. | 03-29-2012 |
20130052968 | REDUCED CLOCK FEED-THROUGH SYSTEMS, METHODS AND APPARATUS - Implementations of radio frequency switch controllers within the scope of the appended claims are configured to reduce the impact of the clock signal induced spurs. In particular, implementations of switch controllers described herein include a poly-phase clocking scheme, as opposed to a single phase to clock the charge pump stages of an negative voltage generator. In some implementations poly-phase clocking schemes reduce the clock signal induced spurs and may preclude the need for additional on-chip or off-chip decoupling capacitors that add to the cost and physical size of a complete front end module solution. | 02-28-2013 |
20140300334 | APPARATUS AND METHODS FOR VOLTAGE CONVERTER BYPASS CIRCUITS - Apparatus and methods for voltage converter bypass circuits are provided. In one embodiment, a voltage conversion system includes a bypass circuit and a voltage converter including an inductor and a plurality of switches configured to control a current through the inductor. The bypass circuit includes a first p-type field effect transistor, a second p-type field effect transistor, a first n-type field effect transistor, and a second n-type field effect transistor. The first and second n-type field effect transistors are electrically in series between a first end and a second end of the inductor. Additionally, the first and second p-type field effect transistor transistors are electrically connected in series between the first end and the second end of the inductor. | 10-09-2014 |